The GLP is committed to full transparency. Download and review our 2019 Annual Report

‘We need it now’: Why precision medicine isn’t doing enough for children with cancer

| | January 14, 2020

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Precision medicine, the concept of giving the right treatment to the right patient at the right time, is flourishing in cancer treatment. But there is a blind spot: children are not benefiting enough from the progress we’re making.

We need a full-scale renaissance in pediatric drug development and care. And we need it now.

For too long, children have been treated with a one-size-fits-all approach. But as we learn that the biology of cancer is different in children than it is in adults — driven by different mechanisms and with different mutations — there is a pressing need for therapies designed just for children. It is time to change the standard of care for pediatric cancer patients. We need to rely less on chemotherapies that damage healthy cells, which can leave survivors with lifelong health challenges, and advance safer, more effective treatments based on precision medicine that target cancer precisely without harming the rest of the body.

Related article:  Bayer asks appellate court to toss $78 million glyphosate-cancer verdict

I believe that precision medicine is the path forward for progress in treating pediatric cancer. But it will take a full-scale, global effort to deploy it.

Read full, original post: Precision medicine has a blind spot: children with cancer

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend